Journal of Clinical Oncology
Articles in this Issue
Upfront surgery versus neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma.
e16472 Background: There is no clear consensus regarding treatment sequence for resectable pancreatic ductal adenocarcinom...
OncoSEGUE: Transforming cancer care delivery through a decentralized, community-integrated oncology model in Southern Portugal.
e13536 Background: Geographic dispersion, limited oncology capacity, and heavy dependence on medical transport pose major...
Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC).
3626 Background: For patients (pts) with dMMR stage III colon cancer, the addition of atezolizumab (atezo) to adjuvant 5-f...
Antibody-mediated targeting of secretory protein SCUBE3 for cancer treatment.
e15098 Background: In the landscape of cancer treatment, chemotherapy is the common treatment option for TNBC. However, re...
Phase I study of liposomal irinotecan plus fruquintinib as third- or later-line therapy for metastatic colorectal cancer.
e15571 Background: Despite advances in therapeutic strategies, patients (pts) with metastatic colorectal cancer (mCRC) hav...
Immunotherapy and the sequence relative to survival outcomes in SCLC: Analysis of the National Cancer Database.
e20123 Background: Small-cell lung cancer (SCLC) remains an aggressive malignancy with limited therapeutic progress over t...
Validation of electronic phenotyping algorithms for prostate cancer in All of Us and their impact on genetic association studies.
1619 Background: The All of Us Research Program enables large scale population-bas...
Racial and regional disparities in prostate cancer–associated dementia mortality in the United States, 1999–2020: A CDC WONDER analysis.
e17023 Background: As prostate cancer (PC) survival improves, age-related comorbidities, including dementia, increasingly...
The influence of timing: A retrospective analysis of short-course TKI induction and survival outcomes in refractory MSS colorectal cancer.
e15573 Background: The concurrent use of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has sho...
HIGHLIGHT 1: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor–positive breast cancer who are receiving adjuvant endocrine therapy.
TPS642 Background: Breast cancer is the most common cause of death due to malignant neoplasms in women globally. Adjuvant...
Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i).
1025 Background: CDK4/6i ± aromatase inhibitors is a preferred tx for pts with HR+/HER2- mBC in the 1L setting. While a su...
External validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1–high metastatic non–small cell lung cancer.
2534 Background: Immune checkpoint inhibitor (ICI) monotherapy is a standard first-line treatment for patients with metast...
Racial and ethnic differences in colorectal cancer screening effectiveness in the PLCO trial.
e15687 Background: Colorectal cancer (CRC) screening has been shown to reduce CRC-related mortality, yet substantial racia...
Predictors of pathologic complete response following neoadjuvant TCHP in HER2-positive breast cancer.
e12519 Background: In HER2+ breast cancer (BC), pathologic complete response (pCR) following HER2-directed neoadjuvant the...
The procedural position of multi-cancer early detection (MCED) in cancer screening paradigm: A simulation modelling study.
e23138 Background: While multi-cancer early detection (MCED)—a promising approach using one blood sample to detect multipl...
Trended real-world analysis of drug-treated mCRPC: Assessment of a diagnostic and co-management gap despite community practices managing a higher-risk population.
e17038 Background: the management of metastatic castration-resistant prostate cancer (mCRPC) is increasingly complex, dema...
Early lessons from the implementation of a pan-African clinico-genomic cancer platform: The African Cancer Atlas.
10602 Background: Limited representation of African populations in cancer genomics constrains the clinical applicability o...
Real-world comparative effectiveness of decitabine/cedazuridine plus venetoclax versus azacitidine plus venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia.
e18533 Background: Older and medically unfit patients with Acute Myeloid Leukemia (AML) are unable to tolerate intensive i...
A phase I/II study of CDX-1140, a CD40 agonist, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results.
4129 Background: Second line therapy shows limited efficacy in biliary tract carcinoma (BTC). We have demonstrated potent...
Nutritional care practices in oncology services in Senegal: A multicenter health services research audit.
e23115 Background: Malnutrition is a major yet under-addressed determinant of outcomes in cancer care. Its impact on morbi...
A complement atlas of head and neck squamous cell carcinomas to reveal intratumoral complement control and identify factor H as a therapeutic target in oral cavity and HPV-negative oropharyngeal tumors.
e18049 Background: Oral Cavity Squamous Cell Carcinoma (OCSCC) and HPV-negative oropharyngeal SCC (HPV-negative OPSCC) tog...
Minimal residual disease dynamics in newly diagnosed multiple myeloma and impact on progression-free survival: A cohort study.
7570 Background: Minimal residual disease (MRD) is a sensitive tool for evaluating treatment response in multiple myeloma...
From infancy to young adulthood: Exploring the divergent genomic mechanisms that drive AML.
6544 Background: Pediatric & young adult Acute Myeloid Leukemias (pAML & YA AML) are an uncommon, heterogenous, &a...
JAK inhibitors vs traditional therapy for myelofibrosis; A meta-analysis of randomized clinical trials.
e18603 Background: Myelofibrosis (MF) is a type of myeloproliferative neoplasm. The pharmacological standard of care is th...
Second primary lung cancer in lung cancer survivors: Clinical characterization and screening.
e22532 Background: Lung cancer survivors remain at risk for second primary lung cancers (SPLC). However, optimal surveilla...